Market Overview

ELIQUIS Reduces Stroke and Systemic Embolism Compared to Warfarin in ARISTOTLE trial

Bristol-Myers
Squibb NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the reductions in stroke or
systemic embolism, major bleeding and mortality demonstrated with ELIQUIS®
compared to warfarin in the ARISTOTLE trial were consistent across a
wide range of stroke and bleeding risk scores in patients with
nonvalvular atrial fibrillation. These results of a subanalysis from the
ARISTOTLE clinical trial were published today in The Lancet.

Stroke and bleeding risk were based on the CHADS2, CHA2DS2VASc,
and HAS-BLED scores, which are patient assessment tools used by
physicians to help predict the risk of stroke and of bleeding in
patients with atrial fibrillation. Physicians can use these risk scores

See full press release

Posted-In: News Guidance Asset Sales Management Global

 

Related Articles (BMY + PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters